Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
To assess the effect of an angiotensin receptor blocker (ARB) on serum potassium and the effect of a serum potassium change on renal outcomes in patients with type 2 diabetes and nephropathy.
Original languageEnglish
Issue number1
Pages (from-to)44-50
Number of pages7
Publication statusPublished - 2011

    Research areas

  • Angiotensin II Type 1 Receptor Blockers, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Female, Humans, Losartan, Male, Middle Aged, Potassium

ID: 34674608